News / Information - Zantac 25 (ranitidine hydrochloride effervescent) EFFERdose Tablets Discontinuation

Jan 28, 2013

0173-0734-00

Effective immediately, GlaxoSmithKline (GSK) will discontinue Zantac 25 (ranitidine hydrochloride effervescent) EFFERdose Tablets.

This website is funded and developed by GSK. This site is intended for US healthcare professionals only.

Trademarks are owned by or licensed to the GSK group of companies.

©2019 GSK group of companies or its licensor. Produced in USA.